Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry

Name: Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry
Creator: Lieneke Ariëns
Published: 2020-09-04T16:49:34.657Z
Keywords: Dermatology

Ariëns, Lieneke

doi:10.17632/j7mxzzbhc5.1

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry

Published: 4 September 2020| Version 1 | DOI: 10.17632/j7mxzzbhc5.1

Contributor:

Lieneke Ariëns

Description

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry

Description

Files

Categories

Licence